THTakuya Hashimoto

Takuya Hashimoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takuya Hashimoto has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Kazuo Shin-Ya

    National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan

    11 shared publications
  • Junko Hashimoto

    Japan Biological Informatics Consortium 2-4-7 Aomi Koto-ku Tokyo 135-0064 Japan

    8 shared publications
  • Haruo Ikeda

    Kitasato Institute for Life Sciences, Kitasato University, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan

    5 shared publications
  • Ikuko Kozone

    Japan Biological Informatics Consortium (JBIC), Tokyo, Japan

    5 shared publications
  • Hikaru Suenaga

    National Institute of Advanced Industrial Science and Technology 2-4-7 Aomi Koto-ku Tokyo 135-0064 Japan

    4 shared publications
  • Shunji Takahashi

    Natural Product Biosynthesis Research Unit RIKEN Center for Sustainable Resource Science 2-1 Hirosawa Wako Saitama 351-0198 Japan

    4 shared publications

Latest Publications

  • Open Access

    Skeletal editing via multi-step engineering of a modular polyketide synthase

    by Kei Kudo, Takuya Hashimoto, Takayoshi Awakawa, Lihan Zhang, Takehiro Nishimura, Junko Hashimoto, Ikuko Kozone, Noritaka Kagaya, Hikaru Suenaga, Adrian T. Keatinge-Clay, et al.

    Assembly line biosynthesis creates numerous structurally diverse natural products using a common modular synthetic strategy. The collinearity between the architectures of modular polyketide synthases (PKS) and the structures of their polyketide products would seem to render these biosynthetic machineries excellent platforms for designer biosynthesis, yet reliable strategies to reprogram these assembly lines without diminishing their activities have not been identified. Here, as a best practice for PKS engineering, we demonstrate the reprogramming of the mediomycin PKS without significant loss of productivity. Using in vitro CRISPR/Cas9 gene editing followed by heterologous expression, we reconstruct an inaccessible drug lead of the fibrinogen receptor, tetrafibricin, at 82 ± 3 mg/L yield, retaining 26% productivity after five-step module editing using an evolution-supported cut site, downstream of the acyltransferase domain. A macrocyclic aminopolyol is also accessed through thioesterase swapping. These results pave the way toward the rational reprogramming of PKSs to access desired complex organic molecules.


  • Application of Cas9‐Based Gene Editing to Engineering of Nonribosomal Peptide Synthetases

    by Takuya Hashimoto, Hikaru Suenaga, Kazuo Shin‐Ya

    Engineering of nonribosomal peptide synthetases (NRPSs) could transform the production of bioactive natural product derivatives. A number of recent reports have described the engineering of NRPSs without marked reductions in yield. Comparative analysis of evolutionarily related NRPSs can provide insights regarding permissive fusion sites for engineering where recombination may occur during evolutionary processes. Studies involving engineering of NRPSs using these recombination sites showed that they have great potential. Moreover, we highlight recent advances in engineering of NRPSs using CRISPR‐associated protein 9 (Cas9)‐based gene editing technology. The use of Cas9 facilitates the editing of even larger biosynthetic gene clusters (BGCs) close to or over 100 kb in size by precisely targeting and digesting DNA sequences at specific sites. This technology combined with growing understanding of potential fusion sites from large‐scale informatics analyses will accelerate the scalable exploration of engineered NRPS assembly lines to obtain bioactive natural product derivatives in high yields.


  • In Vitro Module Editing Of NRPS Enables Production Of Highly Potent Gq‐Signaling Inhibitor FR900359 Derived From Unculturable Plant Symbiont

    by Takuya Hashimoto, Hikaru Suenaga, Keita Amagai, Junko Hashimoto, Ikuko Kozone, Shunji Takahashi, Kazuo Shin‐Ya

    Heterotrimeric G proteins are key mediators in the signaling of G protein‐coupled receptors (GPCR) that are involved in a plethora of important physiological processes and thus major targets of pharmaceutical drugs. The cyclic depsipeptides YM‐254890 and FR900359 are strong and selective inhibitors of the Gq subfamily of G proteins. FR900359 was first reported to be produced by unculturable plant symbiont, however, a culturable FR900359 producer was discovered recently by the standard strategy, screening of the producing strain from the environment. As another strategy, we introduce herein the different way to supply natural compounds of unculturable microorganism origin. We therefore embarked on constructing an artificial biosynthetic gene cluster (BGC) for FR900359 with YM‐254890 BGC as a template using “in vitro module editing” technology, first developed for the modification of type‐I PKS BGCs, to edit YM‐254890 BGC. The resulting artificial BGCs coding FR900359 were heterologously expressed in the Pseudomonas putida KT2440 host strain.

  • In Vitro Module Editing Of NRPS Enables Production Of Highly Potent Gq‐Signaling Inhibitor FR900359 Derived From Unculturable Plant Symbiont

    by Takuya Hashimoto, Hikaru Suenaga, Keita Amagai, Junko Hashimoto, Ikuko Kozone, Shunji Takahashi, Kazuo Shin‐Ya

    Heterotrimeric G proteins are key mediators in the signaling of G protein‐coupled receptors (GPCR) that are involved in a plethora of important physiological processes and thus major targets of pharmaceutical drugs. The cyclic depsipeptides YM‐254890 and FR900359 are strong and selective inhibitors of the Gq subfamily of G proteins. FR900359 was first reported to be produced by unculturable plant symbiont, however, a culturable FR900359 producer was discovered recently by the standard strategy, screening of the producing strain from the environment. As another strategy, we introduce herein the different way to supply natural compounds of unculturable microorganism origin. We therefore embarked on constructing an artificial biosynthetic gene cluster (BGC) for FR900359 with YM‐254890 BGC as a template using “in vitro module editing” technology, first developed for the modification of type‐I PKS BGCs, to edit YM‐254890 BGC. The resulting artificial BGCs coding FR900359 were heterologously expressed in the Pseudomonas putida KT2440 host strain.


  • A novel oxazole-containing tetraene compound, JBIR-159, produced by heterologous expression of the cryptic trans-AT type polyketide synthase biosynthetic gene cluster

    by Takuya Hashimoto, Junko Hashimoto, Noritaka Kagaya, Takehiro Nishimura, Hikaru Suenaga, Makoto Nishiyama, Tomohisa Kuzuyama, Kazuo Shin-Ya

    Using genome mining approach, we identified a novel biosynthetic gene cluster containing trans-AT type PKS genes from Streptomyces versipellis 4083-SVS6. A bacterial artificial chromosome (BAC) clone, pKU503JL68_PN1_P10-C12, accommodating the entire biosynthetic gene cluster was obtained from a BAC library. Heterologous expression of the biosynthetic gene cluster in Streptomyces lividans TK23 led to the production of a novel polyene compound, JBIR-159. We report herein the biosynthetic gene cluster for JBIR-159, and the heterologous expression, isolation, structure determination and a brief biological activity.


  • Open Access

    In vitro Cas9-assisted editing of modular polyketide synthase genes to produce desired natural product derivatives

    by Kei Kudo, Takuya Hashimoto, Junko Hashimoto, Ikuko Kozone, Noritaka Kagaya, Reiko Ueoka, Takehiro Nishimura, Mamoru Komatsu, Hikaru Suenaga, Haruo Ikeda, et al.

    One major bottleneck in natural product drug development is derivatization, which is pivotal for fine tuning lead compounds. A promising solution is modifying the biosynthetic machineries of middle molecules such as macrolides. Although intense studies have established various methodologies for protein engineering of type I modular polyketide synthase(s) (PKSs), the accurate targeting of desired regions in the PKS gene is still challenging due to the high sequence similarity between its modules. Here, we report an innovative technique that adapts in vitro Cas9 reaction and Gibson assembly to edit a target region of the type I modular PKS gene. Proof-of-concept experiments using rapamycin PKS as a template show that heterologous expression of edited biosynthetic gene clusters produced almost all the desired derivatives. Our results are consistent with the promiscuity of modular PKS and thus, our technique will provide a platform to generate rationally designed natural product derivatives for future drug development.


  • Identification, cloning and heterologous expression of biosynthetic gene cluster for desertomycin

    by Takuya Hashimoto, Ikuko Kozone, Junko Hashimoto, Hikaru Suenaga, Manabu Fujie, Noriyuki Satoh, Haruo Ikeda, Kazuo Shin-Ya

    From our in-house microbial genome database of secondary metabolite producers, we identified a candidate biosynthetic gene cluster for desertomycin from Streptomyces nobilis JCM4274. We report herein the cloning of the 127-kb entire gene cluster for desertomycin biosynthesis using bacterial artificial chromosome vector. The entire biosynthetic gene cluster for desertomycin was introduced in the heterologous host, Streptomyces lividans TK23, with an average yield of more than 130 mg l−1.


  • Novel macrolactam compound produced by the heterologous expression of a large cryptic biosynthetic gene cluster of Streptomyces rochei IFO12908

    by Takuya Hashimoto, Ikuko Kozone, Junko Hashimoto, Reiko Ueoka, Noritaka Kagaya, Manabu Fujie, Noriyuki Sato, Haruo Ikeda, Kazuo Shin-Ya

    In the course of our studies on the heterologous expression of giant biosynthetic genes, we discovered a novel cryptic biosynthetic gene cluster in Streptomyces rochei IFO12908. During our efforts to express biosynthetic genes using the host SUKA strain derived from Streptomyces avermitilis, a novel polyene macrolactam compound designated as JBIR-156 was produced. We report herein the cloning and heterologous expression of the JBIR-156 biosynthetic gene cluster, and the isolation, structure determination, and cytotoxic activity of this novel compound.


  • Biosynthesis of Quinolidomicin, the Largest Known Macrolide of Terrestrial Origin: Identification and Heterologous Expression of a Biosynthetic Gene Cluster over 200 kb

    by Takuya Hashimoto, Junko Hashimoto, Ikuko Kozone, Keita Amagai, Teppei Kawahara, Shunji Takahashi, Haruo Ikeda, Kazuo Shin-Ya

    Quinolidomicin A1 is the largest macrolide compound from terrestrial sources, consisting of a 60-membered ring, and its biosynthetic gene cluster was revealed to be over 200 kb. The gene cluster for quinolidomicin was cloned and heterologously expressed. Confirmation of the product led to a structural revision, in which the hydroxy group in the chromophore moiety of the reported structure was replaced by an amine group.


  • Characterization of bafilomycin biosynthesis in Kitasatospora setae KM-6054 and comparative analysis of gene clusters in Actinomycetales microorganisms

    by Ayako Nara, Takuya Hashimoto, Mamoru Komatsu, Makoto Nishiyama, Tomohisa Kuzuyama, Haruo Ikeda

    Bafilomycins A1, C1 and B1 (setamycin) produced by Kitasatospora setae KM-6054 belong to the plecomacrolide family, which exhibit antibacterial, antifungal, antineoplastic and immunosuppressive activities. An analysis of gene clusters from K. setae KM-6054 governing the biosynthesis of bafilomycins revealed that it contains five large open reading frames (ORFs) encoding the multifunctional polypeptides of bafilomycin polyketide synthases (PKSs). These clustered PKS genes, which are responsible for bafilomycin biosynthesis, together encode 11 homologous sets of enzyme activities, each catalyzing a specific round of polyketide chain elongation. The region contains an additional 13 ORFs spanning a distance of 73 287 bp, some of which encode polypeptides governing other key steps in bafilomycin biosynthesis. Five ORFs, BfmB, BfmC, BfmD, BfmE and BfmF, were involved in the formation of methoxymalonyl-acyl carrier protein (ACP). Two possible regulatory genes, bfmR and bfmH, were found downstream of the above genes. A gene-knockout analysis revealed that BfmR was only a transcriptional regulator for the transcription of bafilomycin biosynthetic genes. Two genes, bfmI and bfmJ, were found downstream of bfmH. An analysis of these gene-disruption mutants in addition to an enzymatic analysis of BfmI and BfmJ revealed that BfmJ activated fumarate and BfmI functioned as a catalyst to form a fumaryl ester at the C21 hydroxyl residue of bafilomycin A1. A comparative analysis of bafilomycin gene clusters in K. setae KM-6054, Streptomyces lohii JCM 14114 and Streptomyces griseus DSM 2608 revealed that each ORF of both gene clusters in two Streptomyces strains were quite similar to each other. However, each ORF of gene cluster in K. setae KM-6054 was of lower similarity to that of corresponding ORF in the two Streptomyces species.